Shots:

• Catalent Biologics will provide vial filling and packaging capacity to AstraZeneca at its manufacturing facility in Italy and prepare for large-scale commercial supply of AZD1222
• The agreement ramps up the production of AZD1222 and will prepare the facility to enable round-the-clock manufacturing schedules and supply hundreds of millions of doses of AZD1222 from Aug’2020 to Mar’2022
• The collaboration allows AstraZeneca to meet the global target of supplying 2B doses of its potential COVID-19 vaccine. Catalent’s 28-000 square-meter facility in Anagni offers extensive capabilities in aseptic liquid filling for biologics and sterile products across multiple vial sizes

Click here to read full press release/ article 

Ref: Catalent | Image: Catalent